



King's Research Portal

DOI:

[10.1186/s40479-018-0086-8](https://doi.org/10.1186/s40479-018-0086-8)

Document Version

Publisher's PDF, also known as Version of record

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Moukhtarian, T. R. H., Mintah, R. S., Moran, P. A., & Asherson, P. J. E. (2018). Emotion dysregulation in attention-deficit/ hyperactivity disorder and borderline personality disorder. *Borderline personality disorder and emotion dysregulation*, 5(9). <https://doi.org/10.1186/s40479-018-0086-8>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

REVIEW

Open Access



Emotion dysregulation in attention-deficit/hyperactivity disorder and borderline personality disorder

Talar R. Moukhtarian^{1*}, Ruth S. Mintah¹, Paul Moran^{2†} and Philip Asherson^{1†}

Abstract

There is ongoing debate on the overlap between Attention-Deficit/Hyperactivity Disorder (ADHD) and Borderline Personality Disorder (BPD), particularly regarding emotion dysregulation (ED). In this paper, we present a narrative review of the available evidence on the association of these two disorders from several standpoints. First, we discuss the unique and shared diagnostic criteria for ADHD and BPD, focusing particularly on ED. We consider the methodology of ecological momentary assessment and discuss why this approach could be an alternative and more accurate way to qualitatively distinguish between ADHD and BPD. We summarise key findings on the genetic and environmental risk factors for ADHD and BPD and the extent to which there are shared or unique aetiological and neurobiological risk factors. Finally, we discuss the clinical relevance of considering both disorders in the assessment of patients presenting with trait-like behavioural syndromes, distinguishing the two conditions and implications for treatment.

Keywords: ADHD, BPD, Emotion dysregulation, Symptomatic overlap

Background

In recent years, a debate has ensued over the nosological distinction between Attention-Deficit/Hyperactivity Disorder (ADHD) and Borderline Personality Disorder (BPD) [1]. Impulsivity, irritability and other symptoms of emotional dysregulation are characteristically seen in both disorders, and the nature of the relationship between ADHD and BPD requires clarification [2]. Key questions that arise include the extent to which: 1) ADHD and BPD co-occur; 2) they reflect distinct disorders or alternative expressions of the same underlying disorder; 3) they share common genetic or environmental risk factors; and 4) one of the disorders give a synergistic effect, reinforcing the other or complicating both [3, 4].

In this review paper, we present a narrative description of the available evidence on the association between ADHD and BPD pertaining specifically to emotional dysregulation (ED). We start by presenting an account of the main diagnostic features of each disorder and

outlining the clinical features that are common to BPD and ADHD, then summarising studies that have reported on comorbidity between the two disorders. We then review findings from studies that have measured ED in ADHD and BPD using experience sampling methods, as this provides a precise and ecologically valid way of assessing the phenomenon of ED. Finally, we discuss the extent to which there are shared genetic and environmental risks, and shared neurobiology, for the two disorders, before considering implications of these findings for treatment.

Attention-deficit/hyperactivity disorder

ADHD is a common neurodevelopmental disorder emerging in childhood or early adolescence, characterised by a pervasive pattern of developmentally inappropriate levels of inattention and/or hyperactivity-impulsivity that lead to clinically significant functional and psychosocial impairments [5]. The disorder affects around 5% of children [6]. Longitudinal follow-up studies of children with ADHD show that symptoms of ADHD commonly persist into adulthood, with around two-thirds of cases meeting either full or sub-threshold criteria in adulthood [7]. The prevalence of adult ADHD

* Correspondence: talar_rita.moukhtarian@kcl.ac.uk

†Equal contributors

¹King's College London, MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, London SE5 8AF, UK

Full list of author information is available at the end of the article



in epidemiological surveys is estimated at around 2.5–4% [8–10]. Although ADHD is recognised as a predominantly male disorder in childhood (clinic-referred children are more likely to be male), in adult samples the gender difference is less pronounced [11].

Apart from the main symptoms used to classify ADHD, ED is considered to be an associated feature supporting the diagnosis of ADHD [5, 12]. In ADHD, ED is characterised by problems with temper control (feelings of irritability and frequent outburst of short duration) [13], emotional over-reactivity (diminished ability to handle typical life stresses, resulting in frequent feelings of being hassled and overwhelmed) [13], and mood lability (short and unpredictable shifts from normal mood to depression or mild excitement) [13].

According to the Diagnostic and Statistical Manual of Mental Disorders (DSM–5), the diagnosis of ADHD requires six out of nine ADHD symptoms of either inattention or hyperactivity/impulsivity in childhood, and five out of nine in adults (Table 1). Additional criteria include childhood age of onset defined as several ADHD symptoms present before the age of 12 years, pervasiveness defined as symptoms present in two or more settings, and impairment defined as interference with or reduced quality of social, academic or occupational functioning [14].

The symptom profile and severity of ADHD varies greatly between individuals, with both inattention and hyperactivity/impulsivity associated with functional impairment in multiple domains [2, 15]. ED has also been found to be an independent predictor of impairment in ADHD, after controlling for the confounding effects of core ADHD symptoms (inattention and hyperactivity/impulsivity) on impairment [16–18]. Furthermore, this

has been found in cases of ADHD with no co-existing mental health disorders, and therefore cannot be explained by co-occurring conditions [16]. Impairments can be severe, impacting on education, occupation, social and interpersonal relationships [2, 15]. Adults with ADHD are more likely to have lower educational attainment, poorer work performance and an increased likelihood of dismissal from work [19–21], as well as difficulties in maintaining long-term social relationships and higher divorce rates [22], serious transport accidents [23] and criminality [24].

ADHD seldom exists in isolation and up to 90% of adults with ADHD are reported to have one or more co-occurring mental health disorders [25]. Of these disorders, the most prevalent include mood, anxiety and substance use disorders [3, 26], and personality disorders including BPD [27, 28]. This exceptionally high comorbidity rate could however reflect, at least in part, an artefact of overlapping symptoms shared by mental health disorders [12].

Borderline personality disorder

BPD is a complex and severe mental health disorder, with typical symptom onset during adolescence and presence of behavioural precursors in childhood, persisting into adulthood [5]. BPD is characterised by a pervasive pattern of unstable interpersonal relationships, pronounced impulsive and self-damaging behaviour, unstable identity, and difficulties with ED [5], which substantially impact in an enduring way on quality of life and psychosocial functioning [29]. The DSM-5 diagnosis of BPD requires the pervasive presence of a minimum of five out of nine symptoms (Table 2) [5].

Table 1 DSM-5 symptom criteria for attention deficit hyperactivity disorder [5]

Inattentive symptoms	Hyperactivity symptoms
<ul style="list-style-type: none"> • Fails to give close attention to details or makes careless mistakes in schoolwork, work, or during other activities • Has difficulty sustaining attention in tasks or play activities • Does not seem to listen when spoken to directly • Does not follow through on instructions and fails to finish schoolwork, chores, or duties in the workplace • Has difficulty organising tasks and activities • Avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort • Often loses things necessary for tasks or activities • Easily distracted by extraneous stimuli • Forgetful in daily activities 	<ul style="list-style-type: none"> • Fidgets with or taps hands or feet or squirms in seat • Leaves seat in situations when remaining seated is expected • Runs about or climbs, or is restless in situations where it is inappropriate • Unable to play or engage in leisure activities quietly • “On the go” acting as if “driven by a motor” • Talks excessively
Associated features supporting the diagnosis	Impulsivity symptoms
<ul style="list-style-type: none"> - Emotional dysregulation (low frustration tolerance, emotional over-reactivity, or mood lability, as featured in the Wender-Utah adult ADHD criteria)^a - Mild delays in language, motor, or social development - Impaired academic or work performance^a - Increased risk of suicide attempts by early adulthood, primarily when comorbid with mood, conduct or substance use disorders^a 	<ul style="list-style-type: none"> • Blurts out answers before questions have been completed • Has difficulty waiting turn • Interrupts or intrudes on others

^aBehavioural symptoms that commonly overlap with BPD diagnosis

Table 2 DSM-5 symptom criteria for borderline personality disorder [5]

1. Frantic efforts to avoid real or imagined abandonment
2. A pattern of unstable^a and intense interpersonal relationships
3. Impulsivity in at least two areas that are potentially self-damaging^a
4. Identity disturbance: markedly and persistently unstable self-image or sense of self
5. Recurrent suicidal behaviour, gestures, or threats, or self-mutilating behaviour
6. Affective instability due to a marked reactivity of mood^a
7. Chronic feelings of emptiness
8. Inappropriate, intense anger or difficulty controlling anger^a
9. Transient, stress-related paranoid ideation or severe dissociative symptoms

Associated features supporting the diagnosis

- Recurrent job losses, interrupted education, and separation or divorce are common^a

^aBehavioural symptoms that commonly overlap with ADHD diagnosis

In the general population, BPD has a prevalence of around 6% [30] and within populations of adult psychiatric inpatients, prevalence is around 20% [5]. Most epidemiological surveys report no gender differences of BPD, yet studies of clinical populations typically report higher prevalence figures in women than in men. The different sex ratios in clinical and population samples may be explained by both assessment and sampling biases [30].

Like ADHD, individuals with BPD commonly present with comorbid mental health disorders. In particular, around 90% of BPD cases are reported to have co-occurring mood disorders including depression and dysthymia [31], along with a high prevalence of substance use disorders in the range of 15% to 57% [32].

Overlap in ADHD and BPD

Studies of the co-morbidity between ADHD and BPD

Psychiatric comorbidity is commonly found across all mental health disorders [33] and is defined as the presence of two or more disorders in the same individual at a given time. In principle, each of the disorders should make a unique contribution to the clinical presentation of the individual [34]. However, estimates of comorbidity prevalence may be inflated if there is marked overlap in the symptom criteria of two disorders, leading to poor diagnostic delineation i.e. artefactual co-morbidity [35]. Furthermore, it remains unclear to what extent psychiatric diagnoses reflect entirely distinct disorders, rather than overlapping syndromes [34]. This is a particular problem for psychiatry since there are, as yet, no validated biomarkers or other objective markers with sufficient sensitivity or specificity to be used in clinical practice to distinguish aetiologically distinct mental health conditions. Regarding ADHD and BPD, while the specific symptoms used to classify the two disorders are different, many clinical characteristics are shared, including ED, impulsive risk-taking behaviour, and unstable interpersonal relationships.

A high prevalence of co-occurring ADHD and BPD is consistently reported in the literature. In a large in- and outpatient cohort of 372 adults with ADHD referred for ADHD assessment and treatment at a tertiary referral centre, 27.2% also met criteria for BPD assessed by the structured clinical Interview for DSM-IV II (SCID II) [36]. Similarly, in another sample of 335 adults referred by family physicians, community health clinics or self-referred, BPD, assessed by the SCID-II, was reportedly present in 10% of participants with DSM-IV inattentive subtype ADHD (six or more symptoms in inattention) and 24% of participants with combined subtype ADHD (six or more symptoms of both inattention and hyperactivity/impulsivity) [26]. Likewise, in a sample of 181 adult patients diagnosed with BPD by general practitioners and referred for treatment, 38.1% had comorbid ADHD, with 22.7% meeting the combined type criteria [37].

In a sample of 118 adult women from out-patient clinics seeking treatment for BPD, a high co-occurrence rate was reported: 41.5% met criteria for childhood ADHD (assessed retrospectively), and 16.1% met current criteria for the DSM-IV combined subtype, as well as meeting ADHD criteria as children [38]. However, as opposed to the previous studies where diagnoses was confirmed by clinical interviews [26, 36, 37], severity of borderline personality disorder and ADHD symptoms were assessed using self-report questionnaires [38].

In a sample of adolescents ($n = 107$) with emerging BPD drawn from a European research project investigating the phenomenology of BPD in adolescence, the prevalence of ADHD was 11%, an estimate that was not attenuated even when excluding symptoms of impulsivity accounting for possible symptom overlap [39]. This rate was close to the 16% rate found by Philipsen and colleagues, where current ADHD symptoms was assessed by self-report measures [38], as opposed to clinician-based interviews. Moreover, the samples significantly differed in regard to participants' age.

Regarding population samples, results from the National Epidemiologic Survey on Alcohol and Related Conditions of more than $n = 34,000$ adults, found that lifetime comorbidity with BPD in the ADHD population was 33.7% compared with a lower prevalence of BPD of only 5.2% in the general population [40].

Symptomatic overlap

There is considerable overlap in the symptoms of BPD and the associated features of ADHD (Table 3). Considering the onset and developmental trajectory, both disorders can be considered 'developmental' in the sense that they both emerge during childhood or adolescence and reflect enduring trait-like (non-episodic) symptoms and behaviours. The shared general features of trait-like symptoms that characterise both ADHD and BPD;

Table 3 Overlapping features between ADHD and BPD

ADHD	BPD
<ul style="list-style-type: none"> • Childhood or early adolescent onset (note: recent literature highlights early adult onset in some cases) [115] • Chronic (trait-like) symptoms and persistent course • Pattern of unstable interpersonal relationships is a common associated characteristic • Affective instability is common associated characteristic • Risk taking behaviour (behavioural impulsivity) is an associated characteristic • Inappropriate anger or difficulty controlling anger is a common associated characteristic 	<ul style="list-style-type: none"> • Adolescent or early adult onset • Chronic (trait-like) symptoms and persistence course • Pattern of unstable interpersonal relationships • Affective instability • Behavioural impulsivity/risk taking • Inappropriate anger or difficulty controlling anger

means that differentiating between these diagnoses cannot easily be established by considering age of onset and course of symptoms. This means that to a large extent, differential diagnosis is based on the specific symptoms and behaviours used to define the two disorders.

The most noticeable overlap among the core symptoms used to classify both conditions is impulsivity [1, 39]. Nevertheless, there are important qualitative differences in the manifestation of impulsivity used in the classification of ADHD and BPD. In ADHD, impulsivity refers to difficulty waiting or taking turn, blurting out during conversations (e.g. interrupting or talking over people), and intruding on others (e.g. butting into conversations or activities, taking over what others are doing) [5]. These impulsive symptoms are not always severe in adults with ADHD, but when severe can lead to impairment in social functioning and self-damaging or risk-taking behaviour. The consequences of severe impulsivity in ADHD include reckless driving, promiscuity, interpersonal relationship problems and aggressive behaviour [41, 42]. In BPD, impulsivity is defined by self-damaging behaviour, such as reckless driving, shoplifting, spending, binge eating, substance abuse and promiscuity [5]. People with either of these disorders may therefore display impulsive risk-taking behaviour, but from a diagnostic point of view they are core symptom of the BPD diagnosis, but only an associated feature of ADHD.

The other key area of symptom overlap is ED. This reflects a core symptom domain in the diagnostic classification of BPD [5], whereas in ADHD it is recognised as an associated clinical feature that supports the diagnosis [43, 44]. Nevertheless, ED is commonly seen to accompany ADHD, even in non-comorbid cases [35], and is an independent source of psychosocial impairment. This draws strong comparisons with ED in BPD, particularly when the ED that accompanies ADHD is severe [45]. At

a descriptive level, the emotional symptoms of ADHD were well captured by Wender, Reimherr and colleagues in the earlier Wender-Utah criteria for ADHD, and show substantial overlap with the ED symptoms in the DSM-5 BPD criteria [1, 3, 38].

ED is a dimensional construct [46], referring to rapid and exaggerated changes in emotional states such as heightened irritability or hot temper [45]. A review by Asherson and colleagues reported that ED is present in 72–90% of adults with ADHD, and independently of other symptoms of ADHD predicts impairments in social, educational and occupational domains [47]. In contrast, ED is one of the core symptom domains of individuals with BPD, who nearly always suffer from severe persistent affective instability, inner tension and difficulty controlling emotions such as anger [27, 38, 48, 49]. Despite similarities, it has been suggested that patients with BPD have higher frequency and intensity of affective instability and aggressive impulsive reactions, compared to adults with ADHD [1, 49, 50]. Others describe ADHD patients as being high novelty seekers, who regulate their emotions through extreme external stimulation (e.g. sexual activity, aggressive behaviour), as opposed to those with BPD who tend to engage in self-mutilating behaviour to alleviate negative affect and inner tension [48]. However, self-harming behaviour and suicidality in ADHD has been highlighted in recent literature [51]. Yet, phenomenologically, ED is a complex construct, with shared characteristics in both ADHD and BPD, particularly pertaining to feelings of heightened anger and difficulty controlling anger (criterion eight in BPD) [38]. Others suggest that emotional instability reflects a similar cyclothymic temperament pattern in both disorders [52]. Overall, it remains unclear whether the type of ED seen in ADHD really is qualitatively similar or different from that seen in BPD. One way to investigate this issue with precision is by using ambulatory assessments.

ED in ambulatory assessments

Emotions are time- and context-dependent processes which are not adequately captured by retrospective and cross-sectional reports [53]. Yet, within clinical environments, assessment of ED relies entirely on interviews and self-report rating scales, which may be highly subjective and based on retrospective recall. These methods limit the validity of assessments of fluctuating emotional symptoms by the reliance on the individual's memory, the skills of the interviewer, and may be coloured by their mental state at the time of the assessment [53, 54]. For instance, it has been reported that BPD patients fail to remember their most extreme and intense mood changes [55]. One approach with greater ecological validity is the use of ecological momentary assessments (EMA), also known as ambulatory assessments or

experience sampling, which use repeated ratings of real time experiences [56]. EMA provides an effective way of precisely measuring emotional dynamics and variation within individuals, over time [57, 58].

In BPD, several EMA studies have investigated the dynamics of emotional instability [50, 53, 59–61]. In one study of 50 BPD and 50 healthy controls using 24-h ambulatory monitoring (intervals of 15 min), the BPD group was found to overestimate emotions with negative valence and underestimate emotions with positive valence, comparing retrospective with EMA ratings [60, 62]. In contrast, the healthy control sample overestimated emotions with positive valence and underestimated emotions with negative valence [60, 62]. Individuals with BPD have also been found to report greater levels of intra-individual variability and short-term fluctuations in overall affect valence. In another study comparing 34 outpatients with BPD and 26 with current depression, using EMA for nearly one month, ratings indicated greater instability (i.e. more changes from one assessment to the next) over time for fear, hostility and sadness in the BPD group [63]. It has also been reported using EMA that compared to healthy controls, BPD patients experience a higher frequency and increased intensity of negative affect and a lower frequency and decreased intensity of positive affect [50, 53, 60, 61]. In addition, a recent review of 34 EMA studies found that BPD patients experience longer duration of aversive tension and therefore a slower return to their baseline affective state [55].

To our knowledge, there has been only one EMA study looking at the dynamics of emotional instability in adults with ADHD [57]. Compared to healthy controls ($n = 47$), patients with ADHD ($n = 41$) showed significantly increased instability and intensity of negative emotions (irritability, frustration and anger). They also showed greater reactivity of negative emotions, such as anger, to 'bad' life events. This study included only males and specifically excluded patients with comorbid conditions [57].

Critically, from the standpoint of contrasting ED in populations of patients with ADHD and BPD, there have been no studies of the phenomenon in both patient groups using the EMA method. Furthermore, additional information could also be collected regarding the naturalistic context and situation when emotional changes occur (e.g. where they are, who they are with, what has just happened); which might identify disorder specific contextual triggers for emotional changes in different disorders. Clearly this area needs more research before conclusions can be drawn about the similarity or differences of ED in BPD and ADHD.

Neurobiological correlates of ED in ADHD and BPD

The overlap in symptoms of emotional dysregulation in ADHD and BPD raises the question of a common

neurobiological substrate for ED in the two conditions. In ADHD two competing hypotheses have been proposed for ED. First, the 'dyscontrol hypothesis' proposes that ED is driven by the same cognitive and neural processes that drive ADHD; for example, deficits in top down executive control, or bottom up state regulation factors [64]. In this model, ED reflects an alternative expression of the same underlying neurocognitive deficits that lead to ADHD symptoms. The alternative 'affectivity hypothesis' states that ED reflects deficits in neural processes related directly to emotional regulation, separate from those that lead to ADHD symptoms [64]. To date the accumulating evidence is pointing to the affectivity hypothesis. Two key publications support this conclusion [65, 66]. First, an investigation of cognitive performance deficits in ADHD (including inhibition, working memory, impulsive responding, slow and variable reaction times) found these were associated with ADHD symptoms independently from ED. [66] This suggests that different processes would explain the presence of ED in ADHD. Subsequently, a resting state functional Magnetic Resonance Imaging (fMRI) study in children with ADHD, found that ED, independently from ADHD, were associated with increased positive intrinsic functional connectivity (iFC) between bilateral amygdala and medial prefrontal regions, and reduced iFC between amygdala and bilateral insula/superior temporal gyrus. These findings suggested that ED is linked to disruptions in emotional control networks, which was not linked directly to ADHD [65].

Regarding BPD there are overlapping findings implicating the central role of emotional control networks. A critical review of fMRI studies conclude that emotional sensitivity, including emotional hypersensitivity and intense emotional reactions, was associated with increased amygdala activity and decreased activity with prefrontal cortical control regions [67]. In particular a consistent decrease in anterior cingulate activity and variable was identified, while the medial and dorsolateral prefrontal areas showed variable activity across studies. Overall, increased limbic and diminished prefrontal cortical activity suggested an impaired fronto-limbic inhibitory network [67].

Resting-state fMRI, contrasting intrinsic functional connectivity before and after an emotion regulation task in patients with BPD, further supports disrupted regulation of emotional circuits. Emotional hypersensitivity in BPD was associated with increased intrinsic connectivity between the amygdala and bilateral insula together with dorsal anterior cingulate cortex, while their impaired control over emotional reactions was associated with diminished intrinsic connectivity between the central executive fronto-parietal regions and salience network [68]. Overall the pattern of findings in relation to

emotion regulation was similar to that reported for ADHD by Hulvershorn and colleagues [65].

The overlap of these findings in relation to ED in the two disorders suggests that there may be a common substrate for ED in the two conditions, involving altered top down and bottom up regulation of amygdala function and neural circuits. However, as we discuss below, evidence-based treatments are entirely different for the two disorders, suggesting that the underlying cause of the disrupted emotional circuits may differ in ADHD and BPD, potentially explaining differences in response to different treatments. Nevertheless, these findings suggest that there could also be common forms of treatment in at least a subset of patients with a comparable neurobiological basis for ED.

Genetic and environmental risk factors

ADHD

It is firmly established that genetic factors play a central role in the aetiology of ADHD. The disorder aggregates among biological relatives of ADHD probands [69, 70], and twin studies estimate heritability in the range of 70–80% for parent and teacher ratings of ADHD symptoms in children, with similar estimates for clinically diagnosed cases of ADHD [69, 70]. In adults, self-rating of ADHD symptoms lead to lower heritability estimates in the range of 30–50% [71]. However, heritability estimates are similar to those seen in children for the clinical diagnosis of ADHD in adults, or when combining parent ratings and self-reports [71–73]. These studies find that the variance in ADHD in both childhood and adulthood is best explained by genetic and non-shared environmental factors, with no role for shared environmental factors independent of genetic influences [71].

Earlier candidate gene studies found significant associations with genetic variation within dopamine and serotonin system genes [74], although these have yet to be replicated using genome-wide approaches. Until recently genome-wide association studies (GWAS) of ADHD had not identified genetic variants that increase the risk of ADHD, although heritability due to the measured genetic variance was estimated to be around 30% [75, 76]. The most recent GWAS using a much larger sample of 20,183 ADHD cases and 35,191 controls identified twelve independent loci above genome-wide levels of significance ($p < 5 \times 10^{-8}$), confirming the existence of numerous common variants of small effect that influence the development ADHD [77]. As these are recent findings, further research examining the role of these variants is required.

BPD

Though not as widely developed as the genetic literature on ADHD, there is a growing body of research

implicating genetic influences in the aetiology of BPD. There is evidence to support familial aggregation of BPD features [78, 79] and findings from twin studies report heritability estimates in the range 35%–67% [80–82]. There is consensus between the studies that the remaining variance may be explained by unique rather than shared environmental influences, similar to ADHD.

To date there have been two GWAS studies of BPD. One study assessed two Dutch cohorts ($n = 7125$) using the Personality Assessment Inventory-Borderline Features Scale and found a promising signal on chromosome 5, which corresponds to *SERINC5*, a protein involved in myelination [83]. Seven single nucleotide polymorphisms (SNPs) in this region had p values between 3.28×10^{-6} and 8.22×10^{-7} , while still remaining below genome-wide levels of significance [83]. The other more recent GWAS study was performed in $n = 998$ BPD patients and $n = 1545$ psychiatric controls [84]. While gene-based analysis yielded two significant genes for BPD, *DPYD* on chromosome 1 (1.20×10^{-6}) and *PKP4* on chromosome 2 (8.24×10^{-7}), no genome-wide significant association was found for any SNP [84]. These specific findings in BPD do not overlap with findings from ADHD.

Common genetic risk factors for BPD and ADHD

Though there is evidence for symptom overlap between the two disorders, to date only one study has explored whether this could reflect overlapping genetic influences. Using a population twin sample, high phenotypic correlation ($r = 0.59$) was found between ADHD symptoms and borderline personality traits; consisting of four subscales- affective instability, identity problems, negative relationships and self-harm [85]. The authors found that the phenotypic correlation was explained by 49% genetic factors and 51% environmental factors, suggesting that shared aetiology could be a cause of comorbidity between ADHD and BPD traits [85]. However no further studies have been conducted looking at this relationship.

Overall twin studies of ADHD and BPD show a similar pattern of genetic versus environmental influences, with slightly higher heritability estimates in most ADHD studies. Yet it is important to note that heritability is also a function of the reliability of the measures being used, with the residual non-shared environment including measurement error. Although for both ADHD and BPD there is no evidence for the main effect of shared environment (environmental effects shared by co-twins that explain co-twin similarity), shared environment may still play a major role through gene by environment interactions. It is therefore likely that for both disorders there are genetically driven individual differences in susceptibility to environmental stressors. The relatively high genetic correlation between ADHD and BPD is based on

the correlation of trait scores in the general population, rather than diagnosed cases, but suggests a considerable degree of underlying shared aetiology that may explain the frequent co-occurrence of ADHD and BPD. Further studies are needed to investigate the genetic overlap between the two disorders, but also the overlap with specific symptom domains such as ED.

Treatment approaches

Treatment approaches to ADHD and BPD are widely divergent. According to evidence-based clinical guidelines, in BPD there is limited evidence that medications reduce borderline personality symptoms, including ED, and psychological treatments are the cornerstone of treatment [86]. In contrast, in ADHD there is good evidence for effects of medication on reducing ADHD symptoms [87–89] and ED [90], and only limited evidence for effects of psychological treatments [91].

Clinical trials support the safety and efficacy of stimulants (methylphenidate, dexamphetamine, lisdexamfetamine) and atomoxetine, with reductions in the ADHD symptoms of inattention, impulsivity and hyperactivity, with moderate to large effects sizes ranging between 0.4 to 0.7 in adults [92–95]. In addition, several randomised controlled trials (RCTs) have evaluated the effects of pharmacological treatments on ED in ADHD patients, and found comparable treatment responses to the primary symptoms of the disorder [13, 17, 96]. These findings are further validated by the results of two recent meta-analyses which found moderate effects of stimulants (methylphenidate, dexamphetamine, amphetamines, lisdexamfetamine) and atomoxetine on ED in ADHD (average Cohen's *d* across studies around 0.4) [90, 97]. In these studies, ED was assessed with various measures including ED subscales of the Wender Reimherr Adult Attention Deficit Disorder Scale, the Behaviour Rating Inventory of Executive Function, the Conner's Adult ADHD Rating Scales and the Brown Attention Deficit Disorder Scale.

In contrast to treatment of ADHD, psychotherapy is regarded as first line treatment for people with BPD [5]. The most common therapies are Transference-focused Therapy [98], Schema Therapy [99], Mentalization-based Treatment [100], Systems Training for Emotional Predictability and Problem Solving, and Dialectical Behaviour Therapy (DBT) [101]. DBT, the most intensively studied intervention for BPD, significantly reduces anger (Standardized Mean Difference (SMD) = -0.83) and self-harm (SMD = -0.54), and improves overall mental health functioning (SMD = 0.65) [102]. Not only is psychotherapy regarded as first line treatment for BPD, UK NICE guidelines stipulate that pharmacological treatments should not be used for managing BPD, nor for individual symptoms or behaviours associated with the disorder [86]. The

guidelines recommend the use of pharmacotherapy only as short term treatment measure during a crisis or in the instance of co-occurring mental health disorders [86].

Currently, there is insufficient data on the treatment of co-occurring BPD and ADHD. With regard to drug treatment, there have been no RCTs of stimulants or atomoxetine in BPD alone or in co-occurring BPD-ADHD cases [90].

There have however been only two case reports [103, 104] of successful methylphenidate treatment in patients with co-occurring BPD and ADHD, and two open-label studies [105, 106]; In one adolescent female-only study, patients with co-occurring ADHD and BPD ($n = 14$) reported significant improvement of BPD symptom severity (SMD = -1.5) and aggressive impulsive behaviour (SMD = -1.31) following treatment with methylphenidate for 12 weeks [105]. In a four-week study of 47 adults looking at effects of methylphenidate in addition to DBT, comorbid ADHD-BPD patients who were on stimulant medication ($n = 24$) showed a statistically significant improvement in anger control (SMD = 0.14), motor impulsiveness (SMD = -0.62), depression (SMD = -1.09) and ADHD severity (SMD = -0.5), compared to those without medication ($n = 23$) [106].

Similarly, there are various psychotherapeutic treatments available for adults with ADHD, who are either unresponsive to stimulants and/or atomoxetine, or in need of adjunctive psychotherapy. There have been two exploratory open label studies [107, 108] examining effects of psychotherapy in adult ADHD. According to the multicentre open label study of $n = 72$ patients with ADHD, an adaption of DBT, addressing emotion regulation, depression, impulse control, stress management, neurobiology of ADHD and ADHD in relationships, DBT has therapeutic benefit for people with ADHD [108]. There was a statistically significant decrease on all psychometric measures in the study after DBT treatment; SMD = -0.74 for the ADHD-Checklist, SMD = -0.5 for the Beck Depression Inventory (BDI) and SMD = -0.34 for the adapted Symptom Check List (SCL-16) measuring agitation, disorganised behaviour, emotion dysregulation and irritability among other traits [108]. Similarly, in the open label pilot study of $n = 8$ patients with ADHD, an adaption of cognitive behavioural therapy led to improvement in the same psychometric elements listed above; ES = 0.99 for the BDI, ES = 2.22 for the ADHD-Checklist and ES = 1.35 for the SCL-16 [107].

There have also been three RCTs of cognitive therapy [109–111] with relatively small sample sizes ($n = 31$, $n = 43$ and $n = 51$ respectively), addressing the effects of psychotherapy (in conjunction with medication in some cases) in adult ADHD that resulted in positive outcomes on all scales measuring severity of ADHD symptoms (ES = 1.2, $d = 1.4$ and, depression, anxiety, anger control and

organisation skills among other outcomes. However, a recent large multicentre RCT of $n = 433$ adult ADHD randomised participants to group psychotherapy (GPT) developed and tailored to the treatment of ADHD, compared to clinical management (CM) reflecting optimal usual clinical care, with both groups randomised to methylphenidate or placebo [112]. While methylphenidate significantly reduced ADHD symptoms compared to placebo ($p = 0.003$), there were no significant differences in ADHD symptoms for those receiving GPT or CM ($p = 0.16$). In fact, in this trial, medication proved to be superior to intensive behavioural therapy, yet the latter resulted in better outcomes when combined with medication as compared with placebo [112].

Overall, while DBT modules and other systematically tailored psychotherapies appear to be helpful in ADHD, it is not yet clear whether they improve the core symptoms of ADHD (inattention, and hyperactivity/impulsivity), and there is insufficient data reported for effects on emotional dysregulation in ADHD [107–113]. This needs further investigation, since the evidence to date is based on relatively small studies, and there has been only one trial of cognitive behavioural therapy in ADHD samples without concomitant medication [112].

Conclusions

In clinical practice, it should be acknowledged that the co-existence of ADHD with BPD may complicate the diagnostic process, and hinder treatment outcomes. Currently, patients with co-occurring ADHD and BPD are often seen by different specialists and provided treatments for one condition or the other, but only rarely for both. In fact, there is lack of empirical data to guide future clinical practice. Beyond the issues of differential diagnosis, there is insufficient awareness within specialist ADHD and BPD services of the potential benefits of treating the other condition. This needs to be addressed because treatment of both conditions may have positive benefits for individuals with overall better control of ADHD and BPD related symptoms and behaviours. Indeed, open clinical trials indicate the value of such a dual treatment approach.

Commonly in BPD patients with co-occurring ADHD, inattention and so called *executive function deficits* (i.e. sustained attention, forgetfulness, planning, organising, working memory), as well as physical restlessness and impatience, lead to difficulties in commitment and adherence to psychological therapies [114]. For example, this could be manifested in difficulties remaining seated, feeling restless and impatient, difficulties focusing on conversations and retaining information during therapy sessions, or insufficient planning and organisation to regularly attend therapy sessions [114].

A further potential benefit in a subpopulation of individuals with co-occurring ADHD and BPD may be a reduction in emotional dysregulation and impulsivity following medication treatment of ADHD. Similarly, psychotherapeutic interventions may be helpful for ADHD cases with high levels of emotional dysregulation with partial or no response to ADHD drug treatments, which could be accounted for by BPD. We therefore advocate a more nuanced approach to the management of people presenting with both ADHD and BPD.

An important question arising from the literature is the specificity of emotional symptoms that are seen in both ADHD and BPD. However, symptoms reflecting dysregulation emotional responses are also seen in other mental health disorders. A recent EMA study examined the dynamics of affective instability in patients with BPD compared with post-traumatic stress disorder and bulimia nervosa [56]. Using the same EMA protocol, all three conditions showed a similar degree of heightened affective instability regarding both the valence of emotional changes, and the level of associated distress [56]. Although BPD is the only disorder for which affective instability is part of the core diagnostic criteria [5], it seems that the specific dynamics of ED in BPD may not be so very different from that seen in other clinical groups.

Given the emerging genetic findings in relation to ADHD and BPD, and the overlap of symptoms such as ED, there may be gains from comparing the cognitive-neural underpinnings for ADHD and BPD, as well as overlapping symptom domains such as ED. At this stage, clinical trials are needed to evaluate the role of both ADHD medication and psychotherapy in the treatment of comorbid ADHD-BPD, and to identify treatment prognostic indicators. Under current circumstances, we suggest that health care professionals involved in diagnosing patients with either BPD or ADHD need to be aware of the potential diagnostic overlap and co-occurrence of these two disorders. Further, there should be sufficient clinical expertise to ensure that patient receive the evidence based treatments they require. This includes the potential benefits of drug treatments for ADHD, and psychotherapy for BPD.

Abbreviations

ADHD: Attention-Deficit/Hyperactivity Disorder; BDI: Beck Depression Inventory; BPD: Borderline Personality Disorder; CM: Clinical Management; DBT: Dialectical behavioural therapy; DSM: Diagnostic and Statistical Manual of Mental Disorders; ED: Emotional dysregulation; EMA: Ecological momentary assessment; fMRI: Functional Magnetic Resonance Imaging; GPT: Group Psychotherapy; GWAS: Genome wide association studies; iFC: Intrinsic functional connectivity; RCT: Randomised controlled trial; SCID-II: Structured clinical Interview for DSM-IV II; SCL: Symptom Check List; SMD: Standardised Mean Difference; SNP: Single nucleotide polymorphisms

Authors' contributions

All authors read and approved the final manuscript.

Competing interests

TRM, RM, PM and PA declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹King's College London, MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, London SE5 8AF, UK. ²Centre for Academic Mental Health, Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 2BN, UK.

Received: 13 November 2017 Accepted: 12 April 2018

Published online: 20 May 2018

References

- Van Dijk FE, et al. Symptomatic overlap between attention-deficit/hyperactivity disorder and borderline personality disorder in women: the role of temperament and character traits. *Compr Psychiatry*. 2012;53(1):39–47.
- Asherson P, et al. Differential diagnosis, comorbidity, and treatment of attention-deficit/hyperactivity disorder in relation to bipolar disorder or borderline personality disorder in adults. *Curr Med Res Opin*. 2014;30(8):1657–72.
- Xenaki LA, Pehlivanidis A. Clinical, neuropsychological and structural convergences and divergences between attention deficit/hyperactivity disorder and borderline personality disorder: a systematic review. *Personal Individ Differ*. 2015;86:438–49.
- Storebø OJ, Simonsen E. Is ADHD an early stage in the development of borderline personality disorder? *Nordic J Psychiatry*. 2014;68(5):289–95.
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.
- Polanczyk G, et al. The worldwide prevalence of ADHD: a systematic review and Meta-regression analysis. *Am J Psychiatr*. 2007;164(6):942–8.
- Brookes K, et al. The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. *Mol Psychiatry*. 2006;11(10):934–53.
- de Graaf R, et al. The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO world mental health survey initiative. *Occup Environ Med*. 2008;65(12):835–42.
- Fayyad J, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. *Br J Psychiatry*. 2007;190(5):402–9.
- Kessler RC, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. *Am J Psychiatry*. 2006;163(4):716–23.
- Rucklidge JJ. Gender differences in attention-deficit/hyperactivity disorder. *Psychiatr Clin N Am*. 2010;33(2):357–73.
- Asherson P, et al. Adult attention-deficit hyperactivity disorder: key conceptual issues. *The Lancet Psychiatry*. 2016;3(6):568–78.
- Reimherr FW, et al. Emotional dysregulation in adult ADHD and response to atomoxetine. *Biol Psychiatry*. 2005;58(2):125–31.
- Epstein JN, Loren REA. Changes in the definition of ADHD in DSM-5: subtle but important. *Neuropsychiatry*. 2013;3(5):455–8.
- ASHERSON P, et al. Adult attention-deficit hyperactivity disorder: recognition and treatment in general adult psychiatry. *Br J Psychiatry*. 2007;190(1):4–5.
- Skirrow C, Asherson P. Emotional lability, comorbidity and impairment in adults with attention-deficit hyperactivity disorder. *J Affect Disord*. 2013;147(1–3):80–6.
- Rösler M, et al. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD. *World J Biol Psychiatry*. 2010;11(5):709–18.
- Asherson P, et al. The effects of atomoxetine on emotional control in adults with ADHD: an integrated analysis of multicenter studies. *European Psychiatry*. 2015;30(4):511–20.
- Gjervan B, et al. Functional impairment and occupational outcome in adults with ADHD. *J Atten Disord*. 2012;16(7):544–52.
- Rösler M, et al. Attention deficit hyperactivity disorder in adults. *World J Biol Psychiatry*. 2010;11(5):684–98.
- Halmøy A, et al. Occupational outcome in adult ADHD: impact of symptom profile, comorbid psychiatric problems, and treatment. *J Atten Disord*. 2009;13(2):175–87.
- Barkley RA, Murphy KR. Impairment in occupational functioning and adult ADHD: the predictive utility of executive function (EF) ratings versus EF tests. *Arch Clin Neuropsychol*. 2010;25(3):157–73.
- Chang Z, et al. Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. *JAMA Psychiatry*. 2014;71(3):319–25.
- Lichtenstein P, Larsson H. Medication for attention deficit-hyperactivity disorder and criminality. *N Engl J Med*. 2013;368(8):776.
- Nutt DJ, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. *J Psychopharmacol*. 2007;21(1):10–41.
- Cumyn L, French L, Hechtman L. Comorbidity in adults with attention-deficit hyperactivity disorder. *Can J Psychiatry*. 2009;54(10):673–83.
- Davidson E, Gastpar M. Attention deficit hyperactivity disorder and borderline personality disorder. *Prog Neuro-Psychopharmacol Biol Psychiatry*. 2005;29(6):865–77.
- van Dijk F, et al. Lifespan attention deficit/hyperactivity disorder and borderline personality disorder symptoms in female patients: a latent class approach. *Psychiatry Res*. 2011;190(2–3):327–34.
- Gunderson JG, et al. Ten-year course of borderline personality disorder: psychopathology and function from the collaborative longitudinal personality disorders study. *Arch Gen Psychiatry*. 2011;68(8):827–37.
- Grant BF, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the wave 2 National Epidemiologic Survey on alcohol and related conditions. *J clin psychiatry*. 2008;69(4):533–45.
- Zanarini MC, et al. Axis I comorbidity of borderline personality disorder. *Am J Psychiatr*. 1998;155(12):1733–9.
- Sharp C, Romero C. Borderline personality disorder: a comparison between children and adults. *Bull Menn Clin*. 2007;71(2):85–114.
- Kessler RC, et al. Lifetime prevalence and age-of-onset distributions of dsm-iv disorders in the national comorbidity survey replication. *Arch Gen Psychiatry*. 2005;62(6):593–602.
- Vella G, Aragona M, Alliani D. The complexity of psychiatric comorbidity: a conceptual and methodological discussion. *Psychopathology*. 2000;33(1):25–30.
- Skirrow C, et al. An update on the debated association between ADHD and bipolar disorder across the lifespan. *J Affect Disord*. 2012;141(2–3):143–59.
- Jacob CP, et al. Co-morbidity of adult attention-deficit/hyperactivity disorder with focus on personality traits and related disorders in a tertiary referral center. *Eur Arch Psychiatry Clin Neurosci*. 2007;257(6):309–17.
- Ferrer M, et al. Comorbid attention-deficit/hyperactivity disorder in borderline patients defines an impulsive subtype of borderline personality disorder. *J Personal Disord*. 2010;24(6):812–22.
- Philipsen A, et al. Attention-deficit hyperactivity disorder as a potentially aggravating factor in borderline personality disorder. *Br J Psychiatry*. 2008;192(2):118–23.
- Speranza M, et al. ADHD in adolescents with borderline personality disorder. *BMC Psychiatry*. 2011;11:158.
- Bernardi S, et al. The lifetime impact of attention-deficit hyperactivity disorder: results from the National Epidemiologic Survey on alcohol and related conditions. *Psychol Med*. 2012;42(4):875–87.
- McNamara J, Vervaeke S-L, Willoughby T. Learning disabilities and risk-taking behavior in adolescents. *J Learn Disabil*. 2008;41(6):561–74.
- McNamara JK, Willoughby T. A longitudinal study of risk-taking behavior in adolescents with learning disabilities. *Learning Dis Res Pract*. 2010;25(1):11–24.
- Wender PH. Attention-Deficit hyperactivity disorder in adults. New York: Oxford University Press; 1995.
- Wood DR, et al. Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report. *Arch Gen Psychiatry*. 1976;33:1453–60.
- Berger A, et al. Multidisciplinary perspectives on attention and the development of self-regulation. *Prog Neurobiol*. 2007;82(5):256–86.
- Shaw P, et al. Emotion dysregulation in attention deficit hyperactivity disorder. *Am J Psychiatr*. 2014;171(3):276–93.
- Asherson P, Kuntsi J, Taylor E. Unravelling the complexity of attention-deficit hyperactivity disorder: a behavioural genomic approach. *Br J Psychiatry*. 2005;187(2):103–5.

48. Philipsen A. Differential diagnosis and comorbidity of attention-deficit/hyperactivity disorder (ADHD) and borderline personality disorder (BPD) in adults. *Eur Arch Psychiatry Clin Neurosci*. 2006;256(Suppl 1):i42–6.
49. Philipsen A, et al. Borderline typical symptoms in adult patients with attention deficit/hyperactivity disorder. *Atten Defic Hyperact Disord*. 2009;1(1):1–8.
50. Ebner-Priemer UW, et al. Psychophysiological ambulatory assessment of affective dysregulation in borderline personality disorder. *Psychiatry Res*. 2007;150(3):265–75.
51. Allely CS. The association of ADHD symptoms to self-harm behaviours: a systematic PRISMA review. *BMC Psychiatry*. 2014;14(1):133.
52. Eich D, et al. Temperamental differences between bipolar disorder, borderline personality disorder, and attention deficit/hyperactivity disorder: some implications for their diagnostic validity. *J Affect Disord*. 2014;169:101–4.
53. Ebner-Priemer UW, Trull TJ. Ecological momentary assessment of mood disorders and mood dysregulation. *Psychol Assess*. 2009;21(4):463–75.
54. Trull TJ, Ebner-Priemer U. The role of ambulatory assessment in psychological science. *Curr Dir Psychol Sci*. 2014;23(6):466–70.
55. Santangelo P, Bohus M, Ebner-Priemer UW. Ecological momentary assessment in borderline personality disorder: a review of recent findings and methodological challenges. *J Personal Disord*. 2012;28(4):555–76.
56. Santangelo P, et al. Specificity of affective instability in patients with borderline personality disorder compared to posttraumatic stress disorder, bulimia nervosa, and healthy controls. *J Abnorm Psychol*. 2014;123(1):258–72.
57. Skirrow C, et al. Everyday emotional experience of adults with attention deficit hyperactivity disorder: evidence for reactive and endogenous emotional lability. *Psychol Med*. 2014;44(16):3571–83.
58. Myin-Germeys I, et al. Experience sampling research in psychopathology: opening the black box of daily life. *Psychol Med*. 2009;39(9):1533–47.
59. Ebner-Priemer UW, et al. Unraveling affective dysregulation in borderline personality disorder: a theoretical model and empirical evidence. *J Abnorm Psychol*. 2015;124(1):186–98.
60. Ebner-Priemer UW, et al. State affective instability in borderline personality disorder assessed by ambulatory monitoring. *Psychol Med*. 2007;37(7):961–70.
61. Ebner-Priemer UW, Sawitzki G. Ambulatory assessment of affective instability in borderline personality disorder. *Eur J Psychol Assess*. 2007;23(4):238–47.
62. Ebner-Priemer UW, et al. A valence-dependent group-specific recall bias of retrospective self-reports: a study of borderline personality disorder in everyday life. *J Nerv Ment Dis*. 2006;194(10):774–9.
63. Trull TJ, et al. Affective instability: measuring a core feature of borderline personality disorder with ecological momentary assessment. *J Abnorm Psychol*. 2008;117(3):647–61.
64. Posner J, Kass E, Hulvershorn L. Using stimulants to treat ADHD-related emotional lability. *Curr Psychiatry Rep*. 2014;16(10):478.
65. Hulvershorn LA, et al. Abnormal amygdala functional connectivity associated with emotional lability in children with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry*. 2014;53(3):351–61. e1.
66. Banaschewski T, et al. Neuropsychological correlates of emotional lability in children with ADHD. *J Child Psychol Psychiatry*. 2012;53(11):1139–48.
67. van Zutphen L, et al. Emotional sensitivity, emotion regulation and impulsivity in borderline personality disorder: a critical review of fMRI studies. *Neurosci Biobehav Rev*. 2015;51:64–76.
68. Baczkowski BM, et al. Deficient amygdala–prefrontal intrinsic connectivity after effortful emotion regulation in borderline personality disorder. *Eur Arch Psychiatry Clin Neurosci*. 2017;267(6):551–65.
69. Epstein JN, et al. Familial aggregation of ADHD characteristics. *J Abnorm Child Psychol*. 2000;28(6):585–94.
70. Sprich S, et al. Adoptive and biological families of children and adolescents with ADHD. *J Am Acad Child Adolesc Psychiatry*. 2000;39(11):1432–7.
71. Brikell I, Kuja-Halkola R, Larsson H. Heritability of attention-deficit hyperactivity disorder in adults. *Am J Med Genet B Neuropsychiatr Genet*. 2015;168(6):406–13.
72. Chang Z, et al. Developmental twin study of attention problems: high heritabilities throughout development. *JAMA Psychiatry*. 2013;70(3):311–8.
73. Larsson H, et al. The heritability of clinically diagnosed attention-deficit/hyperactivity disorder across the life span. *Psychol Med*. 2014;44(10):2223–9.
74. Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. *Hum Genet*. 2009;126(1):51–90.
75. Middeldorp CM, et al. A genome-wide association meta-analysis of attention-deficit/hyperactivity disorder symptoms in population-based Paediatric cohorts. *J Am Acad Child Adolesc Psychiatry*. 2016;55(10):896–905. e6.
76. Neale BM, et al. Meta-analysis of genome-wide association studies of attention deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry*. 2010;49(9):884–97.
77. Demontis D, et al. Discovery of the first genome-wide significant risk loci for ADHD: bioRxiv; 2017. <https://doi.org/10.1101/145581>.
78. Gunderson JG, et al. Family study of borderline personality disorder and its sectors of psychopathology. *Arch Gen Psychiatry*. 2011;68(7):753–62.
79. Zanarini MC, et al. Borderline psychopathology in the first-degree relatives of borderline and Axis II comparison Probands. *J Personal Disord*. 2004;18(5):439–47.
80. Reichborn-Kjennerud T, et al. Structure of genetic and environmental risk factors for symptoms of dsm-iv borderline personality disorder. *JAMA Psychiatry*. 2013;70(11):1206–14.
81. Torgersen S, et al. The heritability of cluster B personality disorders assessed both by personal interview and questionnaire. *J Personal Disord*. 2012;26(6):848–66.
82. Distel MA, et al. Genetic covariance STRUCTURE of the four main features of borderline personality disorder. *J Personal Disord*. 2010;24(4):427–44.
83. Lubke GH, et al. Genome-wide analyses of borderline personality features. *Mol Psychiatry*. 2014;19(8):923–9.
84. Witt SH, et al. Genome-wide association study of borderline personality disorder reveals genetic overlap with bipolar disorder, major depression and schizophrenia. *Translational Psychiatry*. 2017. 7: p. e1155.
85. Distel MA, et al. Borderline personality traits and adult attention-deficit hyperactivity disorder symptoms: a genetic analysis of comorbidity. *Am J Med Genet B Neuropsychiatr Genet*. 2011;156B(7):817–25.
86. Borderline personality disorder. Recognition and management: NICE guideline (CG78); 2009. Available from: <https://www.nice.org.uk/guidance/cg78>.
87. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. *J Clin Psychiatry*. 2010;71(6):754–63.
88. Meszaros A, et al. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. *Int J Neuropsychopharmacol*. 2009;12(8):1137–47.
89. Spencer T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. *Biol Psychiatry*. 2005;57(5):456–63.
90. Moukhtarian TR, et al. Effects of stimulants and atomoxetine on emotional lability in adults: a systematic review and meta-analysis. *Euro Psychiatry*. 2017;44:198–207.
91. Attention Deficit Hyperactivity Disorder. Recognition and management: NICE guideline (CG72) 2008; 2016. Available from: <https://www.nice.org.uk/guidance/cg72>
92. Castells X, et al. Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults. *Cochrane Database Syst Rev*. 2011;6. Art. No.: CD007813. <https://doi.org/10.1002/14651858.CD007813.pub2>.
93. Castells X, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder. *CNS Drugs*. 2011;25(2):157–69.
94. Cunill R, et al. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression. *Pharmacoeconomic Drug Saf*. 2013;22(9):961–9.
95. Koesters M, et al. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. *J Psychopharmacol*. 2009; 23(7):733–44.
96. Wender PH, et al. A one year trial of methylphenidate in the treatment of ADHD. *J Atten Disord*. 2011;15(1):36–45.
97. Lenzi F, et al. Pharmacotherapy of emotional dysregulation in adults with ADHD: a systematic review and meta-analysis. *Neurosci Biobehav Rev*. 2017; 84:359–67.
98. Kernberg OF, et al. Transference focused psychotherapy: overview and update. *Int J Psychoanal*. 2008;89(3):601–20.
99. Kellogg SH, Young JE. Schema therapy for borderline personality disorder. *J Clin Psychol*. 2006;62(4):445–58.
100. Bateman A, Fonagy P. Mentalization based treatment for borderline personality disorder. *World Psychiatry*. 2010;9(1):11–5.
101. Lynch TR, et al. Dialectical behavior therapy for borderline personality disorder. *Annu Rev Clin Psychol*. 2007;3(1):181–205.
102. Stoffers-Winterling JM, et al. Psychological therapies for people with borderline personality disorder. *Cochrane Database Syst Rev*. 2012;8. Art. No.: CD005652. <https://doi.org/10.1002/14651858.CD005652.pub2>.
103. Van Reekum R, Links PS. N of 1 study: methylphenidate in a patient with borderline personality disorder and attention deficit hyperactivity disorder. *Can J Psychiatry*. 1994;39(3):186–7.

104. Hooberman D, Stern TA. Treatment of attention deficit and borderline personality disorders with psychostimulants: case report. *J Clin Psychiatry*. 1984;45(10):441–2.
105. Golubchik P, et al. Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial. *Int Clin Psychopharmacol*. 2008;23(4):228–31.
106. Prada P, et al. Addition of methylphenidate to intensive dialectical behaviour therapy for patients suffering from comorbid borderline personality disorder and ADHD: a naturalistic study. *ADHD Atten Deficit Hyperact Dis*. 2015;7(3):199–209.
107. Hesslinger B, et al. Psychotherapy of attention deficit hyperactivity disorder in adults. *Eur Arch Psychiatry Clin Neurosci*. 2002;252(4):177–84.
108. Philipsen A, et al. Structured group psychotherapy in adults with attention deficit hyperactivity disorder: results of an open multicentre study. *J Nerv Ment Dis*. 2007;195(12):1013–9.
109. Safren SA, et al. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. *Behav Res Ther*. 2005;43(7):831–42.
110. Stevenson CS, et al. A cognitive remediation Programme for adults with attention deficit hyperactivity disorder. *Aust New Zealand J Psychiatry*. 2002;36(5):610–6.
111. Hirvikoski T, et al. Reduced ADHD symptoms in adults with ADHD after structured skills training group: results from a randomized controlled trial. *Behav Res Ther*. 2011;49(3):175–85.
112. Philipsen A, et al. Effects of group psychotherapy, individual counseling, methylphenidate, and placebo in the treatment of adult attention-deficit/hyperactivity disorder: a randomized clinical trial. *JAMA Psychiatry*. 2015;72(12):1199–210.
113. Corbisiero S, et al. Is emotional dysregulation part of the psychopathology of ADHD in adults? *Atten Defic Hyperact Disord*. 2013;5(2):83–92.
114. Matthies SD, Philipsen A. Common ground in Attention Deficit Hyperactivity Disorder (ADHD) and Borderline Personality Disorder (BPD)—review of recent findings. *Borderline Personal Disord Emot Dysregul*. 2014;1(3). <https://doi.org/10.1186/2051-6673-1-3>.
115. Moffitt TE, et al. Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. *Am J Psychiatr*. 2015;172(10):967–77.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

